Novo Nordisk’s obesity drug CagriSema helps obese patients cut weight by 22.7%: Report | Company Business News-OxBig News Network

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday, adding the results were 25  percent they had expected. 

The new findings from the drug candidate deals a blow to the Danish drugmaker’s ambitions for a successor to its popular Wegovy more powerful than Eli Lilly’s Zepbound.